Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. VSports app下载.

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. V体育官网.

. 2013;8(2):e54923.
doi: 10.1371/journal.pone.0054923. Epub 2013 Feb 6.

V体育2025版 - A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors

Markus Thomas  1 , Yvonne Kienast, Werner Scheuer, Monika Bähner, Klaus Kaluza, Christian Gassner, Frank Herting, Ulrich Brinkmann, Stefan Seeber, Anita Kavlie, Martin Welschof, Stefan Ries, K Michael Weidner, Jörg T Regula, Christian Klein
Affiliations

A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors

Markus Thomas et al. PLoS One. 2013.

Abstract (VSports最新版本)

There is increasing experimental evidence for an important role of Angiopoietin-2 (Ang-2) in tumor angiogenesis and progression. In addition, Ang-2 is up-regulated in many cancer types and correlated with poor prognosis. To investigate the functional role of Ang-2 inhibition in tumor development and progression, we generated novel fully human antibodies that neutralize specifically the binding of Ang-2 to its receptor Tie2 VSports手机版. The selected antibodies LC06 and LC08 recognize both rodent and human Ang-2 with high affinity, but LC06 shows a higher selectivity for Ang-2 over Ang-1 compared to LC08 which can be considered an Ang-2/Ang-1 cross-reactive antibody. Our data demonstrate that Ang-2 blockade results in potent tumor growth inhibition and pronounced tumor necrosis in subcutaneous and orthotopic tumor models. These effects are attended with a reduction of intratumoral microvessel density and tumor vessels characterized by fewer branches and increased pericyte coverage. Furthermore, anti-Ang-2 treatment strongly inhibits the dissemination of tumor cells to the lungs. Interestingly, in contrast to the Ang-2/Ang-1 cross-reactive antibody LC08 that leads to a regression of physiological vessels in the mouse trachea, the inhibition with the selective anti-Ang-2 antibody LC06 appears to be largely restricted to tumor vasculature without obvious effects on normal vasculature. Taken together, these data provide strong evidence for the selective Ang-2 antibody LC06 as promising new therapeutic agent for the treatment of various cancers. .

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors are employees of Roche Diagnostics GmbH or Affitech Research AS. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials V体育安卓版.

Figures

Figure 1
Figure 1. Anti-tumor activity of LC06 and LC08 in s.c. Colo205 and orthotopic KPL-4 xenograft tumors.
(A) Colo205 tumor (mean 100 mm3) growth curves in female SCID beige mice receiving LC06 and LC08 (10 mg/kg) once weekly i.p. (n = 10, *p<0.0001, Student's t-test). (B) Total Colo205 tumor weight in tumor bearing mice treated with LC06 and LC08 (n = 10, *p<0.0001 compared to control, Student's t-test). (C) KPL-4 orthotopic tumor (mean 90 mm3) growth curves in mice receiving LC06 and LC08 (10 mg/kg) once weekly i.p. (n = 10, *p<0.05 compared to control, Student's t-test). Error bars represent ± SEM. Arrows indicate start of treatment. The results were confirmed in 3 independent experiments.
Figure 2
Figure 2. Effect of LC06 and LC08 treatment on MVD (A and B), vascular coverage (C), vessel area (D), perfusion (E) and vessel branching (F) in Colo205 tumors.
(A) Representative pictures of CD34-stained Colo205 tumors (mean 800 mm3). (B) Quantitative analysis of tumor microvessel density (MVD). MVD was quantified in CD34-stained whole tumor slides. LC06 and LC08 treatment led to a significant reduction of intratumoral MVD (n = 5, *p<0.05 compared to control, Student's t-test). (C) Quantification of vessel coverage calculated as the percentage of desmin-positive vessels in relation to CD34-positive endothelial cells staining in six random regions of 1000×1000 µm per tumor slide. LC06 and LC08 treated tumors showed increased vessel coverage by desmin positive pericytes (n = 5 mice per group, *p<0.05 compared to control, Student's t-test). (D) The average vessel area of intratumoral microvessels were significantly reduced in tumors treated with LC06 and LC08 (n = 5, *p<0.05 compared to control, Student's t-test). (E) Perfusion was assessed based on analysis of TRITC-lectin perfusion and CD34-positive staining in six random regions of 1000×1000 µm per tumor slide. Almost all remaining intratumoral microvessels were perfused in LC06 (93%) and LC08 (97%) treated tumors compared to control (56%) (n = 5 mice per group, *p<0.01). (F) Number of branched intratumoral microvessels was counted in six random regions of 1000×1000 µm per tumor slide and calculated per mm2 and was significantly reduced in tumors treated with LC06 and LC08. LC06 treatment resulted in stronger inhibition of vessel branching compared to pan-Ang-2/-1 treatment via LC08 (n = 5, *p<0.01 compared to control; #p<0.01 compared to LC08, Student's t-test). Results are expressed as mean ± SEM. Scale bars represent 500 µm.
Figure 3
Figure 3. Tumor necrosis in LC06 and LC08 treated Colo205 tumors.
(A) Quantitative image analysis shows 27% of necrotic area in vehicle treated, 51% in LC06 treated and 43% in LC08 treated tumors (n = 5, *p<0.05 compared to control, Student's t-test). Results are expressed as mean ± SEM. Two independent experiments were performed to confirm the results. (B) Representative mosaic images (10x) of vehicle, LC06 or LC08 treatments. Scale bar represents 1.3 mm.
Figure 4
Figure 4. Tumor cell dissemination to the lungs in orthotopic KPL-4 xenograft tumors after LC06 and LC08 treatment.
Treatment with LC06 and LC08 resulted in a significant reduction of disseminated tumor cells to the lungs (n = 10, *p<0.05 compared to control, Student's t-test). The results were confirmed in two independent experiments. Results are expressed as mean ± SEM.
Figure 5
Figure 5. Effect of LC06 and LC08 on quiescent vessels.
(A) Representative immunofluorescent pictures of CD31 stained tracheal whole mount sections of mice treated with control IgG1, LC06 and LC08. (B) Quantification of capillary branching points (in five random regions of 230×520 µm in each mouse whole mount trachea) reveals that pan-Ang-1/Ang-2 inhibition but not selective anti-Ang-2 treatment induced tracheal vessel regression (n = 3–5; *p<0.05 compared to control, Student's t-test). The results were confirmed in two independent experiments. Results are expressed as mean ± SEM. Scale bar represents 100 µm.
Figure 6
Figure 6. Effect of LC06 and LC08 treatment on VEGF-induced corneal angiogenesis.
(A) Angiogenesis was induced by implanting VEGF (300 ng) or vehicle soaked nylaflo discs into the cornea of BALB/c mice. PBS control did not induce vessel outgrowth from the limbus to the disc compared to VEGF positive control. LC06, LC08 and bevacizumab were injected with 10 mg/kg i.v. at the day of disc implantation. Treatment with both anti-Ang-2 antibodies significantly inhibited neoangiogenesis in a comparable range as bevacizumab (n = 5, *p<0.001 compared to VEGF control, Student's t-test). (B) Representative pictures of vehicle, LC06 and LC08 treated mice. The results were confirmed in 3 additional independent experiments. Results are expressed as mean ± SEM.
See this image and copyright information in PMC

References

    1. Kesisis G, Broxterman H, Giaccone G (2007) Angiogenesis inhibitors. Drug selectivity and target specificity. Curr Pharm Des 13: 2795–2809. - PubMed
    1. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, et al. (1996) Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87: 1161–1169. - "V体育官网入口" PubMed
    1. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, et al. (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55–60. - PubMed
    1. Fiedler U, Krissl T, Koidl S, Weiss C, Koblizek T, et al. (2003) Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats. J Biol Chem 278: 1721–1727. - "V体育官网入口" PubMed
    1. Augustin HG, Koh GY, Thurston G, Alitalo K (2009) Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10: 165–177. - PubMed

"V体育安卓版" MeSH terms

LinkOut - more resources